Abstract:Recent research highlights five potential biomarkers—INHBA, MMP7, PSAT1, SLC7A5, and TGFBI—with elevated levels in colorectal cancer tissues and serum of patients, showing promise for non‐invasive CRC detection. These biomarkers exhibit high diagnostic accuracy, suggesting their potential to improve current diagnostic methods and enhance personalized treatment approaches, though further validation and functional studies are required for larger cohorts. Background The pressing need for reliable biomarkers in colorectal cancer (CRC) diagnosis and prognosis is a major global health concern. Current diagnostic methods rely heavily on invasive procedures like colonoscopy, and existing biomarkers such as Carbohydrate Antigen 19‐9 (CA19‐9) and Carcinoembryonic Antigen (CEA) exhibit limitations in accuracy and specificity. Aims This study aims to identify and validate novel biomarkers that can enhance the early detection and diagnostic precision of CRC while overcoming the shortcomings of conventional biomarkers. Materials and Methods Leveraging advancements in genomic and proteomic technologies, gene expression datasets were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). We identified differentially expressed genes (DEGs) and conducted further analyses, including Gene Ontology (GO) enrichment and Protein‐Protein Interaction (PPI) network construction. Five promising biomarkers—INHBA, MMP7, PSAT1, SLC7A5, and TGFBI—were selected based on their robust performance in Receiver Operating Characteristic (ROC) curve analysis. Serum concentrations of these biomarkers were measured in 200 CRC patients and 100 healthy controls. Results The study revealed significantly elevated expression levels of the selected biomarkers in CRC tissues compared to normal tissues. Additionally, serum concentrations of INHBA, MMP7, PSAT1, SLC7A5, and TGFBI were notably higher in CRC patients than in healthy individuals, with Area Under the Curve (AUC) values ranging from 0.8361 to 0.9869 indicating high diagnostic accuracy. Optimal cutoff values for diagnosis ranged from 38.9 pg/mL to 280.7 pg/mL, yielding sensitivity and specificity values between 74.5% and 92.9%. Discussion The findings underscore the potential of INHBA, MMP7, PSAT1, SLC7A5, and TGFBI as effective non‐invasive biomarkers for CRC detection. Their elevated serum concentrations and robust discriminatory abilities highlight their promise in improving diagnostic accuracy and patient outcomes compared to traditional biomarkers. Conclusion The identification and validation of these novel biomarkers represent a significant advancement in CRC diagnosis and management. Further studies are required to validate their clinical applicability in larger cohorts and to elucidate their functional roles in CRC pathogenesis, ultimately enhancing diagnostic strategies and personalized treatment approaches.

Development and Validation of a Panel of Five Proteins As Blood Biomarkers for Early Detection of Colorectal Cancer

Novel Blood-Based, Five-Gene Biomarker Set For The Detection Of Colorectal Cancer

A Proteomic Classifier Panel for Early Screening of Colorectal Cancer: a Case Control Study

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting.

Prospective Evaluation of 64 Serum Autoantibodies As Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting

Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer

Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting

Protein and glycomic plasma markers for early detection of adenoma and colon cancer

Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel

Analysis of blood markers for early colorectal cancer diagnosis

Construction of a fecal immune-related protein-based biomarker panel for colorectal cancer diagnosis: a multicenter study

Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Colorectal Cancer.

Identification and Validation of Serum Biomarkers to Improve Colorectal Cancer Diagnosis

Diagnostic Accuracy of a Blood-Based Biomarker Panel for Colorectal Cancer Detection: A Pilot Study

Serum Unsaturated Free Fatty Acids: A Potential Biomarker Panel for Early-Stage Detection of Colorectal Cancer.

Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma.

Blood Biomarkers Panels for Screening of Colorectal Cancer and Adenoma on a Machine Learning-Assisted Detection Platform

Developing a Novel Non-invasive Serum-based Diagnostic Test for Early Detection of Colorectal Cancer

Blood Autoantibodies Against Tumor-Associated Antigens As Biomarkers in Early Detection of Colorectal Cancer

Blood-derived Molecular Signatures As Biomarker Panels for the Early Detection of Colorectal Cancer